Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. RPID
RPID logo

RPID Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Rapid Micro Biosystems Inc (RPID) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.380
1 Day change
6.05%
52 Week Range
4.940
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Rapid Micro Biosystems Inc (RPID) is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows weak financial performance, insider selling trends, and no significant positive catalysts. Additionally, technical indicators are mixed, and there are no strong trading signals from Intellectia Proprietary Trading Signals.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 43.493, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near key support at 4.213, with resistance levels at 4.511 and 4.696.

Positive Catalysts

  • NULL identified. No recent news or significant events to drive positive sentiment.

Neutral/Negative Catalysts

  • Insider selling has increased by 211.95% over the last month, indicating potential lack of confidence from insiders. The stock has a 40% chance of declining over the next week and month based on candlestick pattern analysis.

Financial Performance

In Q3 2025, revenue increased by 3.08% YoY to $7.838M, but the company remains unprofitable with a net income of -$11.505M (up 1.61% YoY). EPS remains negative at -0.26. Gross margin improved to 8.88%, but overall financials are weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Wall Street analysts forecast RPID stock price to rise
3 Analyst Rating
Wall Street analysts forecast RPID stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.130
sliders
Low
8
Averages
8
High
8
Current: 4.130
sliders
Low
8
Averages
8
High
8
Lake Street
NULL -> Buy
initiated
$8
AI Analysis
2025-07-28
Reason
Lake Street
Price Target
$8
AI Analysis
2025-07-28
initiated
NULL -> Buy
Reason
Lake Street initiated coverage of Rapid Micro Biosystems with a Buy rating and $8 price target. Rapid is \"emerging as the category leader\" in microbial quality control automation with its Growth Direct platform, says the analyst, who believes the market has yet to fully appreciate the already existing scale and growing adoption of Growth Direct. The firm sees further upside as recurring revenue continues to scale given \"the stickiness of the platform,\" the analyst added.

People Also Watch